Overview

Docetaxel, Oxaliplatin and 5-FU in Metastatic Gastric Adenocarcinoma With Inoperable Malignant Bowel Obstruction

Status:
Not yet recruiting

Trial end date:
2024-01-01

Target enrollment:

Participant gender:

Summary

This is a study of docetaxel, oxaliplatin and 5-Fluorouracil for advanced gastric or gastroesophageal junction adenocarcinoma with inoperable malignant bowel obstruction: the triplet regimen will be given as 1st, 2nd or 3rd line treatment to participants. The primary study hypothesis is that the regimen will provide a clinically meaningful Bowel Obstruction Remission.

Phase:

Phase 2

Details

Lead Sponsor:

Sixth Affiliated Hospital, Sun Yat-sen University

Treatments:

Docetaxel
Fluorouracil
Oxaliplatin